RCKT vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and NTLA
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs. Its Competitors
CorMedix (NASDAQ:CRMD) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
CorMedix presently has a consensus target price of $17.14, suggesting a potential upside of 45.40%. Rocket Pharmaceuticals has a consensus target price of $18.60, suggesting a potential upside of 618.15%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than CorMedix.
CorMedix has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
CorMedix has a net margin of 20.81% compared to Rocket Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 22.57% beat Rocket Pharmaceuticals' return on equity.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.3% of CorMedix shares are held by company insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CorMedix has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
In the previous week, Rocket Pharmaceuticals had 20 more articles in the media than CorMedix. MarketBeat recorded 49 mentions for Rocket Pharmaceuticals and 29 mentions for CorMedix. CorMedix's average media sentiment score of 0.44 beat Rocket Pharmaceuticals' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.
Summary
CorMedix beats Rocket Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 7/2/2025 by MarketBeat.com Staff
